Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong · Delayed Price · Currency is HKD 506.00
-14.00 (-2.69%)
At close: Apr 20, 2026
HKG:6990 Revenue
In the year 2025, Sichuan Kelun-Biotech Biopharmaceutical had annual revenue of 2.06B CNY with 6.46% growth. Sichuan Kelun-Biotech Biopharmaceutical had revenue of 1.11B in the half year ending December 31, 2025, with 124.06% growth.
Revenue
2.06B CNY
Revenue Growth
+6.46%
P/S Ratio
51.52
Revenue / Employee
1.01M CNY
Employees
2,045
Market Cap
117.99B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.06B | 124.88M | 6.46% |
| Dec 31, 2024 | 1.93B | 392.55M | 25.48% |
| Dec 31, 2023 | 1.54B | 736.56M | 91.62% |
| Dec 31, 2022 | 803.93M | 771.61M | 2,387.26% |
| Dec 31, 2021 | 32.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 41.59B |
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 19.69B |
| Innovent Biologics | 14.51B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.62B |
| Akeso | 3.40B |
Sichuan Kelun-Biotech Biopharmaceutical News
- 4 months ago - Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq